Verve Therapeutics Names Lyndra’s Bellinger Chief Scientific Officer

Verve Therapeutics has appointed Andrew Bellinger to serve as its chief scientific officer, the same position he held at Lyndra Therapeutics. Bellinger, who is a general cardiologist at Brigham and Women’s Hospital, will continue to serve as an advisor to Lyndra. His experience also includes positions at Cocoon Biotech. Verve is developing a way to edit the genome of people in order to protect them from heart disease. In May, the Cambridge, MA-based biotech raised $58.5 million in Series A financing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.